Can HEPZATO move beyond uveal melanoma? Delcath begins major metastatic breast cancer test
Delcath has dosed the first patient in the DELUMA Phase 2 trial, testing HEPZATO for liver-dominant HER2-negative metastatic breast cancer.
Pharma & Biotech
Pharma & Biotech
Delcath Systems tests whether HEPZATO KIT can move beyond metastatic uveal melanoma
Delcath has a liver-response signal in breast cancer. The harder test is whether HEPZATO KIT can prove value beyond a small cohort.
Pharma & Biotech
ESMO-EURACAN adds CHEMOSAT to uveal melanoma guidance as Delcath Systems strengthens clinical position
Delcath Systems won ESMO-EURACAN guideline recognition for CHEMOSAT in uveal melanoma. Read what this could change for liver-directed cancer care.
Pharma & Biotech
Delcath subgroup data links survival to tumor burden and LDH in uveal melanoma
New Phase 3 subgroup data suggest Delcath’s HEPZATO KIT improves survival in patients with lower tumor burden or LDH. Learn what this means for mUM treatment.
Medical Devices & Diagnostics
Can Delcath’s HEPZATO redefine the treatment window for metastatic uveal melanoma?
New subgroup data on HEPZATO highlights improved survival in low-burden metastatic uveal melanoma. Find out what this changes in clinical strategy.